top of page

All Posts

Sintilimab - Asian-optimized PD-1 checkpoint inhibitor by Lilly and Innovent Biologics

Sintilimab - Asian-optimized PD-1 checkpoint inhibitor by Lilly and Innovent Biologics

Sintilimab - Asian-optimized PD-1 checkpoint inhibitor by Lilly and Innovent Biologics

Dec 17, 20254 min read

Cadonilimab — a PD-1/CTLA-4 bispecific antibody for cervical cancer and other solid tumors

Cadonilimab — a PD-1/CTLA-4 bispecific antibody for cervical cancer and other solid tumors

Cadonilimab — a PD-1/CTLA-4 bispecific antibody for cervical cancer and other solid tumors

Nov 1, 20256 min read

Toripalimab — a PD-1 inhibitor for multiple solid tumors

Toripalimab — a PD-1 inhibitor for multiple solid tumors

Toripalimab — a PD-1 inhibitor for multiple solid tumors

Oct 31, 20256 min read

Fruquintinib, a US FDA-approved inhibitor for metastatic colorectal cancer

Fruquintinib, a US FDA-approved inhibitor for metastatic colorectal cancer

Fruquintinib, a US FDA-approved inhibitor for metastatic colorectal cancer

Feb 3, 20254 min read

Tislelizumab: US FDA approved with superior efficacy in ESCC

Tislelizumab: US FDA approved with superior efficacy in ESCC

Tislelizumab: US FDA approved with superior efficacy in ESCC

Feb 3, 20253 min read

Ivonescimab - Promising Efficacy in NSCLC

Ivonescimab - Promising Efficacy in NSCLC

Ivonescimab - Promising Efficacy in NSCLC

Feb 3, 20253 min read

bottom of page